[1]
Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, Vader J. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart failure reviews. 2019 Mar:24(2):167-176. doi: 10.1007/s10741-018-9757-1. Epub
[PubMed PMID: 30565021]
[2]
Eadie AL, Brunt KR, Herder M. Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan). Pharmacology research & perspectives. 2021 May:9(3):e00794. doi: 10.1002/prp2.794. Epub
[PubMed PMID: 34087050]
Level 3 (low-level) evidence
[3]
Vicent L, Esteban-Fernández A, Gómez-Bueno M, De-Juan J, Díez-Villanueva P, Iniesta ÁM, Ayesta A, González-Saldívar H, Rojas-González A, Bover-Freire R, Iglesias D, García-Aguado M, Perea-Egido JA, Martínez-Sellés M. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry. Journal of cardiovascular pharmacology. 2019 Feb:73(2):118-124. doi: 10.1097/FJC.0000000000000641. Epub
[PubMed PMID: 30540687]
[4]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[5]
Canale ML, Coviello K, Solarino G, Del Meglio J, Simonetti F, Venturini E, Camerini A, Maurea N, Bisceglia I, Tessa C, Casolo G. Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology. Frontiers in cardiovascular medicine. 2022:9():801143. doi: 10.3389/fcvm.2022.801143. Epub 2022 Mar 1
[PubMed PMID: 35299980]
Level 2 (mid-level) evidence
[6]
Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardio-oncology (London, England). 2020 Nov 5:6(1):24. doi: 10.1186/s40959-020-00078-4. Epub 2020 Nov 5
[PubMed PMID: 33292750]
[7]
Du AX, Westerhout CM, McAlister FA, Shanks M, Oudit GY, Paterson DI, Hanninen M, Thomas J, Ezekowitz JA. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. Journal of cardiovascular pharmacology. 2019 Mar:73(3):149-154. doi: 10.1097/FJC.0000000000000643. Epub
[PubMed PMID: 30540684]
[8]
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016 Mar 15:133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Epub
[PubMed PMID: 26976916]
[9]
. In brief: Sacubitril/valsartan (Entresto) expanded indication. The Medical letter on drugs and therapeutics. 2021 May 3:63(1623):65
[PubMed PMID: 33976096]
Level 3 (low-level) evidence
[10]
Cada DJ, Baker DE, Leonard J. Sacubitril/Valsartan. Hospital pharmacy. 2015 Nov:50(11):1025-36. doi: 10.1310/hpj5011-1025. Epub 2015 Nov 24
[PubMed PMID: 27621510]
[11]
Kulmatycki KM, Langenickel T, Ng WH, Pal P, Zhou W, Lin TH, Rajman I, Chandra P, Sunkara G. Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
. International journal of clinical pharmacology and therapeutics. 2017 Sep:55(9):728-739. doi: 10.5414/CP202988. Epub
[PubMed PMID: 28737127]
[13]
Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC. Heart failure. 2019 Jan:7(1):1-12. doi: 10.1016/j.jchf.2018.06.011. Epub 2018 Nov 7
[PubMed PMID: 30414818]
[15]
Fala L. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. American health & drug benefits. 2015 Sep:8(6):330-4
[PubMed PMID: 26557227]
[16]
McCullough PA, Mehta HS, Barker CM, Van Houten J, Mollenkopf S, Gunnarsson C, Ryan M, Cork DP. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction. Clinical cardiology. 2021 Sep:44(9):1192-1198. doi: 10.1002/clc.23664. Epub 2021 Aug 3
[PubMed PMID: 34342033]
[17]
Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL Jr, Yancy CW. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2023 May 9:81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19
[PubMed PMID: 37137593]
Level 3 (low-level) evidence